Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.32 |
| ▸ | TPMT | P51580 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970199 | 0.83 | PDE2A (0.52) | PDE2AKDM1AHAO1PTGS1AKR1C3 | |
| SCHEMBL21919349 | 0.76 | PDE2A (0.32) | PDE2A | |
| SCHEMBL4623454 | 0.75 | PDE2A (0.33) | PDE2A | |
| SCHEMBL17431626 | 0.73 | PDE2A (0.46) | PDE2AKDM1AHAO1PTGS1AKR1C3 | |
| SCHEMBL944794 | 0.71 | PDE2A (0.44) | PDE2AKDM1AHAO1CA1CA2 | |
| SCHEMBL67142 | 0.71 | — | — | |
| SCHEMBL10597056 | 0.71 | HDAC8 (0.50) | TPMTHDAC8CA1CA2 | |
| SCHEMBL18656576 | 0.69 | PDE2A (0.42) | PDE2AKDM1AHAO1PTGS1AKR1C3 | |
| SCHEMBL944658 | 0.69 | LMNA (0.50) | PDE2AKDM1AHAO1 | |
| SCHEMBL21585264 | 0.69 | PDE2A (0.48) | PDE2AKDM1AHAO1PTGS1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596561-A1 | PHOSPHORUS-CONTAINING COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Suzhou Genhouse Bio Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20240151993-A1 | ELECTRON WITHDRAWING GROUP (EWG)-CONTAINING ORGANIC MOLECULES FOR IMPROVED OPTICAL PROPERTIES IN AR/VR COMPONENTS | META PLATFORMS TECHNOLOGIES, LLC | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009055749-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009005470-A1 | ARYL AND HETEROARYL SUBSTITUTED ISOINDOLE DERIVATIVES AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008150217-A1 | 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONE ANALOGS FOR THE INHIBITION OF BETA-SECRETASE | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080287460-A1 | NEW COMPOUNDS 835 | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080200540-A1 | ANTIPARASITIC AGENTS | PFIZER LIMITED (GB) | 2008-08-21 | — | — | US | disclosed |
| US-20080200553-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-7375138-B2 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| CN-1653044-A | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | AVENTIS PHARMA DEUTSHCHLAND GM (DE) | 2005-08-10 | — | — | CN | disclosed |
| US-20030216476-A1 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | AVENTIS PHARMA DEUTSHCHLAND GMBH (DE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287460-A1 | NEW COMPOUNDS 835 | GRIK5, MAPT, PSEN1 | PDE2A 266/4885KDM1A 2603/4885HAO1 2781/4885 |
| US-20080200553-A1 | PENTAFLUOROSULFANYLBENZOYLGUANIDINES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AIDS, AND MEDICAMENTS COMPRISING THEM | TNNI3, TNNT2, SDHB | PDE2A 1969/4885KDM1A 3739/4885HAO1 2918/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | PDE2A 4399/4885KDM1A 4486/4885HAO1 3669/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | PDE2A 4399/4885KDM1A 4486/4885HAO1 3669/4885 |
| US-20240151993-A1 | ELECTRON WITHDRAWING GROUP (EWG)-CONTAINING ORGANIC MOLECULES FOR IMPROVED OPTICAL PROPERTIES IN AR/VR COMPONENTS | AR, OR10J3, ESRRG | PDE2A 1054/4885KDM1A 1930/4885HAO1 2585/4885 |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV2, TRPV3 | PDE2A 1408/4885KDM1A 3001/4885HAO1 2661/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | PDE2A 792/4885KDM1A 4873/4885HAO1 4589/4885 |
| US-20030216476-A1 | Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them | TNNI3, TNNT2, SDHB | PDE2A 1948/4885KDM1A 3563/4885HAO1 2650/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | PDE2A 4399/4885KDM1A 4486/4885HAO1 3669/4885 |
| US-20080200540-A1 | ANTIPARASITIC AGENTS | ACHE, MPO, ABCB11 | PDE2A 501/4885KDM1A 4038/4885HAO1 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.